Phase i and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction

Investigational New Drugs

Volumn 31, Issue 3, 2013, Pages 724-733

  Delord, J P ^a   Ravaud, A ^b   Bennouna, J ^c   Fumoleau, P ^d   Favrel, S ^e   Pinel, M C ^e   Ferre P ^e   Saliba, F ^f  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^f HÔPITAL PAUL BROUSSE   (France)

Author keywords

Liver dysfunction Pharmacokinetics; Phase I; Vinflunine

Indexed keywords

4 O DEACETYLVINFLUNINE; CYTOCHROME P450 3A4; DRUG METABOLITE; UNCLASSIFIED DRUG; VINFLUNINE;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER PATIENT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CLEARANCE; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FECES; FEMALE; FEVER; HUMAN; INFECTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; INFUSIONS, INTRAVENOUS; LIVER DISEASES; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; TUBULIN MODULATORS; VINBLASTINE;

EID: 84879073979     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-012-9878-7     Document Type: Article

References (16)

1. Kruczynski A, Colpaert F, Tarayre JP, et al. (1998) Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother Pharmacol 41:437-447
2. Kruczynski A, Barret JM, Etievant C, et al. (1998) Antimitotic and tubulin-interacting properties of vinflunine, a novel fluorinated Vinca alkaloid. Biochem Pharmacol 55:635-648
3. Barret JM, Etievant C, Limouzy A, et al. (1999) In vitro synergistic effects of anticancer drugs in combination with Vinflunine, a novel fluorinated Vinca alkaloid. Proc Annu Meet Am Assoc Cancer Res 40
4. Bennouna J, Fumoleau P, Armand JP, et al. (2003) Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. Ann Oncol 14:630-637
5. Frampton JE, Moen MD (2010) Vinflunine. Drugs 70:1283-1293
6. Focan C, Kreutz F, Leroy I, et al. (2001) Pharmacokinetics and mass-balance elimination of 3 H-Vinorelbine following I.V. and oral administration to patients. Proc Annu Meet Am Assoc Cancer Res 383(Abst):2064
7. Lobert S, Puozzo C (2008) Pharmacokinetics, metabolites, and preclinical safety of vinflunine. Semin Oncol 35:S28-S33
8. Zorza G, Pellerin D, Fortune V, Puozzo C (2010) A simple and sensitive high-performance liquid chromatographic method for the determination of vinflunine and 4-O-deacetylvinflunine from human blood. Ther Drug Monit 32:734-740
9. Johnson P, Geldart T, Fumoleau P, et al. (2006) Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks. Invest New Drugs 24:223-231
10. Vermorken JB, Stupp R, Nguyen L (2003) Phase I study of IV vinflunine given on a weekly schedule in previously untreated patients with advanced solid tumours. Proc Am Soc Clin Oncol 22:221, Abstract 887
11. Stolinsky DC, Bogdon DL, Pugh RP, et al. (1973) Vinblastine (NSC-49842) plus vincristine (NSC-67574) given in intensive 3-day courses as therapy for lymphomas, sarcomas, and other neoplasms. Cancer Chemother Rep 57:481-484
12. Çömezoglu N, Zhang D, Yao M, et al. (2008) Potential of Vinflunine to Inhibit or to Induce Cytochrome P450 Enzymes and the Role of Esterases in the Formation of the Major Metabolite 4-O-Deacetyl Vinflunine. Proc.ISSX San Diego; Poster
13. Verbeeck RK (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64:1147-1161
14. Donelli MG, Zucchetti M, Munzone E, et al. (1998) Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 34:33-46
15. Robieux I, Sorio R, Borsatti E, et al. (1996) Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther 59:32-40
16. Kitzen JJ, Puozzo C, de Jonge MJ, et al. (2010) Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer 46:266-269